# US 2022/0008523 A1 · Peptide conjugated particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008523 A1
- Document ID: US20220008523A1
- Status: Published application
- Kind: A1
- Application number: 17/482,043
- Filed: 2021-09-22
- Published: 2022-01-13
- Earliest claimed: 2013-08-13
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Lonnie D. Shea; Stephen D. Miller; Jonathan Woon Teck Yap; Daniel R. Getts; Derrick McCarthy
- Web page: https://patentgrep.com/patent/US20220008523A1

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K 47/6911: {the form being a liposome}
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/577: {tolerising response}
- A61K 2039/622: {non-covalent binding}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

## Claims

### Claim at position 1

1-91. (canceled)

### Claim 92

A composition comprising a negatively charged liposome comprising encapsulated antigens or one or more antigenic epitopes, wherein the particle has a negative zeta potential of between −30 mV to −100 mV.

### Claim 93 (depends on 92)

The composition of claim 92, wherein the liposome has a negative zeta potential of between −30 mV to −80 mV.

### Claim 94 (depends on 92)

The composition of claim 92, wherein the liposome has a diameter of between 200 nm to 2000 nm.

### Claim 95 (depends on 94)

The composition of claim 94, wherein the liposome has a diameter of between 400 nm to 800 nm.

### Claim 96 (depends on 92)

The composition of claim 92, wherein the antigen comprises an autoimmune antigen, an antigen expressed on a tissue to be transplanted into a subject, an enzyme for enzyme replacement therapy, or a viral protein.

### Claim 97 (depends on 96)

The composition of claim 96, wherein the antigen is selected from the group consisting of myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta-cell antigen, insulin, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histones, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, aqua porin 4, desmoglein 1, desmoglein 3, nicotinic acetylcholine receptor, gliadin, human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1casein milk allergen, Apig 1 celery allergen, Bere 1 Brazil nut allergen, B-lactoglobulin milk allergen, bovine serum albumin, Cor a 1.04 hazelnut allergen, insulin, proinsulin, islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), zinc transporter 8 isoform (ZnT8), ovalbumin egg allergen, and peanut protein.

### Claim 98 (depends on 96)

The composition of claim 96, wherein the antigen is associated with type 1 diabetes, multiple sclerosis, primary biliary cirrhosis, systemic lupus erythematosus, neuromyelitis optica, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, membranous nephropathy, bullous pemphigoid, pemphigus vulgaris, myasthenia gravis, sclerosing cholangitis, a mucopolysaccharide storage disorder, gangliosidosis, alkaline hypophosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, Gaucher's disease, Fabry's disease, Hurler's disease, Hunter's disease, Maroteaux-Lamy disease, hemophilia A, hemophilia B, von Wilebrand disease, venous thrombosis, purpura fulminans, mucopolysaccaridosis VI, pompe disease, Celiac disease, food allergy, environmental allergy, peanut allergy, or inflammatory bowel disease.

### Claim 99 (depends on 96)

The composition of claim 96, wherein the antigen is selected from the group consisting of SEQ. ID NO: 1, SEQ. ID NO: 14, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 47, SEQ. ID NO: 69, SEQ. ID NO: 84, SEQ. ID NO: 87, SEQ. ID NO: 197, SEQ. ID NO: 388, SEQ. ID NO: 471, SEQ. ID NO: 549, SEQ. ID NO: 564, SEQ. ID NO: 1056, SEQ. ID NO: 1082, SEQ. ID NO: 1121, SEQ. ID NO: 4979, SEQ. ID NO: 1798, SEQ. ID NO: 1987, SEQ. ID NO: 1839, SEQ. ID NO: 2065, SEQ. ID NO: 2266, SEQ. ID NO: 1875, SEQ. ID NO: 1832, SEQ. ID NO: 2012, SEQ. ID NO: 2421, SEQ. ID NO: 1925, SEQ. ID NO: 1838, SEQ. ID NO: 1833, SEQ. ID NO: 1919, SEQ. ID NO: 1824, and SEQ. ID NO: 1815.

### Claim 100

A method of inducing antigen specific tolerance in a subject, the method comprising administering to said subject a composition of a negatively charged liposome comprising encapsulated antigens or one or more antigenic epitopes, wherein the particle has a negative zeta potential of between −30 mV to −100 mV.

### Claim 101 (depends on 100)

The method of claim 100, wherein the liposome has a negative zeta potential of between −30 mV to −80 mV.

### Claim 102 (depends on 100)

The method of claim 100, wherein the liposome has a diameter of between 200 nm to 2000 nm.

### Claim 103 (depends on 102)

The method of claim 102, wherein the liposome has a diameter of between 400 nm to 800 nm.

### Claim 104 (depends on 100)

The method of claim 100, wherein the subject suffers from a disease or condition selected from the group consisting of type 1 diabetes, multiple sclerosis, primary biliary cirrhosis, systemic lupus erythematosus, neuromyelitis optica, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, membranous nephropathy, bullous pemphigoid, pemphigus vulgaris, myasthenia gravis, sclerosing cholangitis, a mucopolysaccharide storage disorder, gangliosidosis, alkaline hypophosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, Gaucher's disease, Fabry's disease, Hurler's disease, Hunter's disease, Maroteaux-Lamy disease, hemophilia A, hemophilia B, von Wilebrand disease, venous thrombosis, purpura fulminans, mucopolysaccaridosis VI, pompe disease, Celiac disease, food allergy, environmental allergy, peanut allergy, or inflammatory bowel disease.

### Claim 105 (depends on 100)

The method of claim 100, wherein the subject is receiving a proteinaceous therapy used in enzyme or coagulation factor replacement.

### Claim 106 (depends on 105)

The method of claim 105, wherein the proteinaceous therapy is selected from the group consisting of Myozyme®, alglucerase, imiglucerase, taliglucerase, agalsidase beta, 1-iduronidase, acid glucosidase, Iduronate-2-sulfatase, N-acetylgalactosamnie-4-sulfatase, antihemophilic factor, factor VII, eptacogalfa, factor VIII, factor IX, miglustat, romiplastim, epotetin alpha, protein C, laronidase, Lumizyme®, or Factor VII.

### Claim 107 (depends on 100)

The method of claim 100, wherein the antigen comprises an autoimmune antigen, an antigen expressed on a tissue to be transplanted into a subject, an enzyme for enzyme replacement therapy, or a viral protein.

### Claim 108 (depends on 100)

The method of claim 100, wherein the antigen is selected from the group consisting of myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta-cell antigen, insulin, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histones, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, aqua porin 4, desmoglein 1, desmoglein 3, nicotinic acetylcholine receptor, gliadin, human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1casein milk allergen, Apig 1 celery allergen, Bere 1 Brazil nut allergen, B-lactoglobulin milk allergen, bovine serum albumin, Cor a 1.04 hazelnut allergen, insulin, proinsulin, islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), zinc transporter 8 isoform (ZnT8), ovalbumin egg allergen, and peanut protein.

### Claim 109 (depends on 100)

The method of claim 100, wherein the antigen is selected from the group consisting of SEQ. ID NO: 1, SEQ. ID NO: 14, SEQ. ID NO: 22, SEQ. ID NO: 23, SEQ. ID NO: 47, SEQ. ID NO: 69, SEQ. ID NO: 84, SEQ. ID NO: 87, SEQ. ID NO: 197, SEQ. ID NO: 388, SEQ. ID NO: 471, SEQ. ID NO: 549, SEQ. ID NO: 564, SEQ. ID NO: 1056, SEQ. ID NO: 1082, SEQ. ID NO: 1121, SEQ. ID NO: 4979, SEQ. ID NO: 1798, SEQ. ID NO: 1987, SEQ. ID NO: 1839, SEQ. ID NO: 2065, SEQ. ID NO: 2266, SEQ. ID NO: 1875, SEQ. ID NO: 1832, SEQ. ID NO: 2012, SEQ. ID NO: 2421, SEQ. ID NO: 1925, SEQ. ID NO: 1838, SEQ. ID NO: 1833, SEQ. ID NO: 1919, SEQ. ID NO: 1824, and SEQ. ID NO: 1815.
